Search Results - "WHITCUP, SCOTT M"

Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data by Gonzalez, Victor H, Campbell, Joanna, Holekamp, Nancy M, Kiss, Szilárd, Loewenstein, Anat, Augustin, Albert J, Ma, Julia, Ho, Allen C, Patel, Vaishali, Whitcup, Scott M, Dugel, Pravin U

“…Abstract Purpose To determine whether early visual acuity response to ranibizumab in diabetic macular edema is associated with long-term outcome. Design…”
Get full text

Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema by Boyer, David S., MD, Yoon, Young Hee, MD, PhD, Belfort, Rubens, MD, PhD, Bandello, Francesco, MD, Maturi, Raj K., MD, Augustin, Albert J., MD, Li, Xiao-Yan, MD, Cui, Harry, MS, Hashad, Yehia, MD, Whitcup, Scott M., MD

“…Purpose To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex, DEX implant) 0.7 and 0.35 mg in the treatment of patients with…”
Get full text

Pharmacology of Corticosteroids for Diabetic Macular Edema by Whitcup, Scott M, Cidlowski, John A, Csaky, Karl G, Ambati, Jayakrishna

“…Corticosteroids remain the mainstay of treatment for inflammatory diseases almost 80 years after their first clinical use. Topical ophthalmic formulations of…”
Get full text

Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion by Haller, Julia A., MD, Bandello, Francesco, MD, Belfort, Rubens, MD, Blumenkranz, Mark S., MD, Gillies, Mark, MD, Heier, Jeffrey, MD, Loewenstein, Anat, MD, Yoon, Young-Hee, MD, Jacques, Marie-Louise, MD, Jiao, Jenny, PhD, Li, Xiao-Yan, MD, Whitcup, Scott M., MD

“…Objective To evaluate the safety and efficacy of dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA) compared with sham in…”
Get full text

Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients by Boyer, David S, Faber, David, Gupta, Sunil, Patel, Sunil S, Tabandeh, Homayoun, Li, Xiao-Yan, Liu, Charlie C, Lou, Jean, Whitcup, Scott M

“…To evaluate the safety and efficacy of Ozurdex (dexamethasone intravitreal implant) 0.7 mg in the treatment of diabetic macular edema in vitrectomized eyes…”
Get full text

Dexamethasone Intravitreal Implant in Combination with Laser Photocoagulation for the Treatment of Diffuse Diabetic Macular Edema by Callanan, David G., MD, Gupta, Sunil, MD, Boyer, David S., MD, Ciulla, Thomas A., MD, Singer, Michael A., MD, Kuppermann, Baruch D., MD, PhD, Liu, Ching-Chi, MS, Li, Xiao-Yan, MD, Hollander, David A., MD, MBA, Schiffman, Rhett M., MD, MHSA, Whitcup, Scott M., MD

“…Purpose To evaluate Ozurdex (dexamethasone intravitreal implant [DEX implant]; Allergan, Inc, Irvine, CA) 0.7 mg combined with laser photocoagulation compared…”
Get full text

Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data by Sadda, Srinivas R., Campbell, Joanna, Dugel, Pravin U., Holekamp, Nancy M., Kiss, Szilárd, Loewenstein, Anat, Augustin, Albert J., Shih, Vanessa, Xu, Xiaoshu, Wykoff, Charles C., Whitcup, Scott M.

“…Background/objectives This post hoc analysis explores the relationship between residual oedema exposure after ranibizumab treatment initiation and long-term…”
Get full text

Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes by Chang-Lin, Joan-En, Burke, James A, Peng, Qing, Lin, Ton, Orilla, Werhner C, Ghosn, Corine R, Zhang, Kai-Ming, Kuppermann, Baruch D, Robinson, Michael R, Whitcup, Scott M, Welty, Devin F

“…To evaluate dexamethasone pharmacokinetics after implantation of a sustained-release dexamethasone (DEX) intravitreal implant in nonvitrectomized and…”
Get full text

Effect of the Duration of Macular Edema on Clinical Outcomes in Retinal Vein Occlusion Treated with Dexamethasone Intravitreal Implant by Yeh, Wei-Shi, PhD, Haller, Julia A., MD, Lanzetta, Paolo, MD, Kuppermann, Baruch D., MD, PhD, Wong, Tien Yin, MD, PhD, Mitchell, Paul, MD, PhD, Whitcup, Scott M., MD, Kowalski, Jonathan W., PharmD, MS

“…Purpose To assess the effect of duration of macular edema (ME) on clinical outcomes after treatment with dexamethasone intravitreal implant 0.7 mg (Ozurdex;…”
Get full text

Eyelash growth in subjects treated with bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel-group study by Smith, Stacy, MD, Fagien, Steven, MD, Whitcup, Scott M., MD, Ledon, Fred, BS, Somogyi, Christine, RN, Weng, Emily, ScD, Beddingfield, Frederick C., MD, PhD

“…Background Bimatoprost 0.03% is associated with increased growth and prominence of eyelashes. Objective We sought to compare the safety and efficacy of…”
Get full text

Cytokine and chemokine levels in tears from healthy subjects by Carreño, Ester, Enríquez‐de‐Salamanca, Amalia, Tesón, Marisa, García‐Vázquez, Carmen, Stern, Michael E., Whitcup, Scott M., Calonge, Margarita

“…Acta Ophthalmol. 2010: 88: e250–e258 . Purpose:  There is growing evidence for the existence of an ‘immune tone’ in normal tears. The aim of this study was to…”
Get full text

The Role of the Immune Response in Age-Related Macular Degeneration by Whitcup, Scott M., Sodhi, Akrit, Atkinson, John P., Holers, V. Michael, Sinha, Debasish, Rohrer, Bärbel, Dick, Andrew D.

“…Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries; with the aging population, the negative health impacts and…”
Get full text

Inflammation in Retinal Disease by Whitcup, Scott M., Nussenblatt, Robert B., Lightman, Susan L., Hollander, David A.

“…[...]evidence has also arisen supporting a prominent role for inflammation underlying the pathogenesis of a wide array of retinal diseases, including…”
Get full text

The History of Botulinum Toxins in Medicine: A Thousand Year Journey by Whitcup, Scott M

“…Botulinum toxin is one of the most potent and deadliest substances on earth. Because of its unique mechanism of action at the synaptic junction and the ability…”
Get more information

Vascular Changes in Eyes Treated with Dexamethasone Intravitreal Implant for Macular Edema after Retinal Vein Occlusion by Sadda, SriniVas, MD, Danis, Ronald P., MD, Pappuru, Rajeev R., MD, Keane, Pearse A., MD, Jiao, Jenny, PhD, Li, Xiao-Yan, MD, Whitcup, Scott M., MD

“…Objective To evaluate the angiographic findings in eyes from 2 clinical trials of the dexamethasone intravitreal implant (DEX implant) 0.7 mg in the treatment…”
Get full text

Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant by Chang-Lin, Joan-En, Attar, Mayssa, Acheampong, Andrew A, Robinson, Michael R, Whitcup, Scott M, Kuppermann, Baruch D, Welty, Devin

“…To determine the pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc.). Thirty-four…”
Get full text

Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis by Whitcup, Scott M., Robinson, Michael R.

“…Uveitis is a group of ocular inflammatory disorders that can lead to severe vision loss. Despite advances in anti‐inflammatory therapy, many patients are…”
Get full text

Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion: Twelve-Month Study Results by HALLER, Julia A, BANDELLO, Francesco, WHITCUP, Scott M, BELFORT, Rubens, BLUMENKRANZ, Mark S, GILLIES, Mark, HEIER, Jeffrey, LOEWENSTEIN, Anat, YOUNG HEE YOON, JIAO, Jenny, LI, Xiao-Yan

“…To evaluate the safety and efficacy of 1 or 2 treatments with dexamethasone intravitreal implant (DEX implant) over 12 months in eyes with macular edema owing…”
Get full text

Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion by Haller, Julia A., MD, Bandello, Francesco, MD, Belfort, Rubens, MD, Blumenkranz, Mark S., MD, Gillies, Mark, MD, Heier, Jeffrey, MD, Loewenstein, Anat, MD, Yoon, Young Hee, MD, Jiao, Jenny, PhD, Li, Xiao-Yan, MD, Whitcup, Scott M., MD

“…Objective To evaluate the safety and efficacy of 1 or 2 treatments with dexamethasone intravitreal implant (DEX implant) over 12 months in eyes with macular…”
Get full text

A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema by Callanan, David G., Loewenstein, Anat, Patel, Sunil S., Massin, Pascale, Corcóstegui, Borja, Li, Xiao-Yan, Jiao, Jenny, Hashad, Yehia, Whitcup, Scott M.

“…Purpose To evaluate whether treatment with dexamethasone intravitreal implant (DEX implant) 0.7 mg every 5 months provides a similar average change in…”
Get full text